Altimmune
ALT
26 hedge funds and large institutions have $1.57M invested in Altimmune in 2018 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 4 increasing their positions, 7 reducing their positions, and 9 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
5.4% less ownership
Funds ownership: 14.03% → 8.64% (-5.4%)
13% less funds holding
Funds holding: 30 → 26 (-4)
43% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 7
44% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 9
64% less capital invested
Capital invested by funds: $4.37M → $1.57M (-$2.8M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
+$306K |
| 2 |
Acadian Asset Management
Boston,
Massachusetts
|
+$90.7K |
| 3 |
RJA
Raymond James & Associates
St Petersburg,
Florida
|
+$63K |
| 4 |
Commonwealth Equity Services
Waltham,
Massachusetts
|
+$16.7K |
| 5 |
Northern Trust
Chicago,
Illinois
|
+$9.28K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
-$813K |
| 2 |
Renaissance Technologies
New York
|
-$328K |
| 3 |
FQ
First Quadrant
Glendale,
California
|
-$202K |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$146K |
| 5 |
Bank of New York Mellon
New York
|
-$137K |
ALT Hedge Fund Activity: Q1 2018 in Review
26 of the 4,373 institutional investors tracked by Wall St. Rank reported a position in Altimmune (ALT) for Q1 2018, worth a combined $1.57M — down 64% from $4.37M a quarter earlier.
Sellers outnumbered buyers: 9 funds closed out of ALT and 5 opened new positions — a net loss of 4 holders — while 7 trimmed existing stakes and 4 added.
The largest buyer was Macquarie Group, adding an estimated $306K. The largest seller was Hudson Bay Capital Management, exiting entirely with an estimated $813K sold.
- 26 institutional investors held Altimmune (ALT) as of Q1 2018, down from 30 in Q4 2017.
- Funds reported $1.57M of Altimmune stock for Q1 2018, down 64% quarter-over-quarter.
- 5 funds opened new Altimmune positions in Q1 2018 and 9 closed out, a net change of -4 holders.
- The largest Altimmune buyer in Q1 2018 was Macquarie Group, an estimated $306K added.
- The largest Altimmune seller in Q1 2018 was Hudson Bay Capital Management, an estimated $813K sold.
Based on aggregated 13F filings for Q1 2018.